Evaluating Kylo-11 for Long-Acting Lipoprotein(a) Suppression

Steven Nissen, MD, and Ashish Sarraju, MD, discuss early clinical data on Kylo-11, a novel therapy that produced substantial reductions in lipoprotein(a) for up to one year after a single injection. Lowering lipoprotein(a), a genetically determined cardiovascular risk factor linked to atherosclerotic disease and aortic stenosis, remains an important focus for preventive cardiology. Learn about the new drug's mechanism and safety findings.  Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.